Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBCBS North Dakota AMD Testing Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North DakotaPolicy 75

    Genetic Testing for Macular Degeneration

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - North Dakota Policy 75 alerts

    Get alerted when Policy 75 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of genetic testing intended to assess risk for developing or progressing age-related macular degeneration or to guide AMD treatment. Genetic testing for macular degeneration is considered investigational under this policy.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyGenetic Testing for Macular Degeneration
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewSep 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionInform members before rendering investigational genetic testing that they may be financially responsible for the cost.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    InvestigationalCoverage status
    InvestigationalAMD testing coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    AMD gene variants in listed assay
    InsufficientEvidence for improved outcomes

    Coverage Criteria

    Genetic Testing for Macular Degeneration

    Genetic testing for macular degeneration is considered investigational.

    Genetic testing for macular degeneration is considered investigational.

    Genetic Testing for AMD

    Genetic testing for AMD is considered investigational because current evidence does not demonstrate improved treatment decisions, surveillance, or health outcomes.

    All of the following apply

    • Routine genetic testing of patients with complex eye diseases, including AMD, or unaffected patients with a family history is not warranted because disease-associated variants are not highly predictive and clinical assessment may be more accurate.
    • Genetic testing is not recommended for patients with neovascular AMD to provide clinically relevant information about response to anti-vascular endothelial growth factor (VEGF) treatment.
    • There is insufficient evidence to support genetic testing for determining nutritional supplement recommendations.
    • There is insufficient evidence that increased monitoring of patients identified as high risk through genetic testing slows AMD progression or improves overall outcomes.
    • There is no clinical evidence that altering management for patients at genetically higher risk of progression results in better visual outcomes.

    Genetic testing for macular degeneration is considered investigational.

    Routine genetic testing of patients with complex eye diseases, including AMD, or unaffected patients with a family history of such diseases, is not warranted. The presence of any one disease-associated variant is not highly predictive of disease development, and standard clinical diagnostic methods may be more accurate for assessing risk of vision loss. The American Academy of Ophthalmology’s 2025 Preferred Practice Pattern also states that routine genetic testing is not recommended at this time because prospective clinical evidence is lacking.

    Genetic testing in patients with neovascular AMD is not recommended to provide clinically relevant information about response to anti-vascular endothelial growth factor (VEGF) treatment.

    Genetic testing is not supported for determining nutritional supplement recommendations because evidence is insufficient. Current preventive measures, including antioxidant and zinc supplementation, do not establish clinical utility for predictive genetic testing.

    Genetic testing is not supported for increasing monitoring of patients identified as high risk because there is insufficient evidence that more frequent monitoring slows AMD progression or improves overall outcomes.

    Coding

    Investigational genetic and molecular testing codesmixedExperimental
    0205UOphthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular degeneration risk associated with zinc supplements
    81408Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis)
    81479Unlisted molecular pathology procedure
    81599Unlisted multianalyte assay with algorithmic analysis

    Provider Actions

    Denial Risk

    Investigational Genetic Testing

    Genetic testing for macular degeneration is considered investigational and is subject to denial.

    Billing Rule

    Contract Exclusion and Member Liability

    Applicable contracts exclude services or procedures considered investigational or cosmetic. Providers may bill members for these services and should inform members before rendering them that they are likely to be financially responsible.

    Note

    Background

    Age-related macular degeneration is a complex disease influenced by genetic and environmental factors and is a leading cause of severe vision loss in people older than age 60. Genetic variants associated with AMD risk and progression have been identified, but current evidence does not demonstrate that genetic test results alter treatment decisions or improve overall health outcomes.

    Definitions

    Pathogenic variant
    DefinitionA variant associated with disease.
    Benign variant
    DefinitionA variant not associated with disease.
    Variant of uncertain significance
    DefinitionA genetic change whose effect on human health is unknown.
    Analytic validity
    Definition

    Not Covered

    Not covered are genetic tests intended to identify individuals at risk of developing advanced AMD, predict progression from early or intermediate AMD to advanced disease, test single or multiple genes associated with advanced AMD, guide AMD treatment or management, determine monitoring or surveillance intensity, predict response to anti-VEGF therapy in neovascular AMD, or guide nutritional supplement recommendations.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyGenetic Testing for Macular Degeneration
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewSep 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionInform members before rendering investigational genetic testing that they may be financially responsible for the cost.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsBackgroundDefinitionsNot Covered

    AMD Genetic Testing Is Investigational

    Genetic testing for age-related macular degeneration (AMD) is investigational because evidence is insufficient to demonstrate that it improves treatment decisions or health outcomes. Routine testing is not recommended by the American Academy of Ophthalmology due to a lack of prospective clinical evidence; disease-associated variants are not highly predictive, and standard clinical assessment may be more accurate. The American Society of Retina Specialists found no evidence that changing management based on genetic risk improves visual outcomes, no clinically relevant information regarding response to anti-VEGF treatment in neovascular AMD, and insufficient evidence to support testing for nutritional supplement recommendations.

    • No preventive measures beyond good health practices have been shown to result from AMD genetic testing.
    • Routine genetic testing may become relevant if clinical trials demonstrate that specific genotypes benefit from specific therapies or surveillance.
    The technical accuracy of a test in detecting a mutation that is present or in excluding a mutation that is absent.
    Clinical validity
    DefinitionThe diagnostic performance of a test—including sensitivity, specificity, and positive and negative predictive values—in detecting clinical disease.
    Clinical utility
    DefinitionWhether test results change patient management and whether those changes produce clinically important improvements in health outcomes.